{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:15:43Z","timestamp":1791512143702,"version":"4.3.4"},"reference-count":77,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutics and Clinical Risk Management"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.2147\/tcrm.2007.3.1.133","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T20:52:55Z","timestamp":1182286375000},"page":"133-148","source":"Crossref","is-referenced-by-count":67,"title":["Adalimumab in the treatment of arthritis"],"prefix":"10.2147","volume":"3","author":[{"given":"Philip J","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","reference":[{"key":"p_1_784","unstructured":"[AB] Abbott Laboratories Press Releases. October 4, 2005. Abbott announces US and EU regulatory submissions seeking approval of HumiraR(adalimumab in ankylosing spondylitis (AS) [online]. Accessed 3 April 2006. URL: http:\/\/www.abbott.com\/news\/ releaseonly.cfm?id=997."},{"key":"p_4_785","unstructured":"Abbott Laboratories Press Releases. April 28, 2006. Abbott's HUMIRAO(adalimumab) receives positive opinion from the European Medicines Agency for the treatment of Ankylosing Spondylitis [online]. Accessed 24 May 2006. URL: http:\/\/www.abbott.com\/news_media_center.cfm"},{"key":"p_5_786","doi-asserted-by":"crossref","unstructured":"Anderson PJ. 2005. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum, 34(5 Suppl 1):19-22.","DOI":"10.1016\/j.semarthrit.2005.01.005"},{"key":"p_6_787","first-page":"S265","volume":"48","author":"Antoni C","year":"2003","journal-title":"Arthritis Rheum"},{"key":"p_7_788","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"p_8_789","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"p_9_790","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"p_10_791","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.60.7.660","volume":"60","author":"Barrera P","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"p_11_792","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"p_12_793","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"p_13_794","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"Braun J","year":"1995","journal-title":"Arthritis Rheum"},{"key":"p_14_795","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"p_15_796","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","volume":"48","author":"Braun J","year":"2003","journal-title":"Arthritis Rheum"},{"key":"p_16_797","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/ard.2003.017160","volume":"64","author":"Breedveld FC","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"p_17_798","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld FC","year":"2006","journal-title":"Arthritis Rheum"},{"key":"p_18_799","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/rheumatology\/36.6.643","volume":"36","author":"Brennan FM","year":"1997","journal-title":"Br J Rheumatol"},{"key":"p_19_800","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/ard.2004.028324","volume":"63","author":"Burmester GR","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"p_20_801","first-page":"S541","volume":"52","author":"Burmester GR","year":"2005","journal-title":"Arthritis Rheum"},{"key":"p_21_802","unstructured":"Burmester G, Mease PJ, Dijkmans BAC, etal 2006. Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis [abstract]. Presented at EULAR 2006. [Citation can be updated with published reference in mid-to late-June.]"},{"key":"p_22_803","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","volume":"41","author":"Catrina AI","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"p_23_804","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/art.21528","volume":"54","author":"Catrina AI","year":"2006","journal-title":"Arthritis Rheum"},{"key":"p_24_805","first-page":"328","volume":"344","author":"Choy EH","year":"2001","journal-title":"N Engl J Med"},{"key":"p_25_806","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.311"},{"key":"p_26_807","first-page":"2563","volume":"30","author":"Furst DE","year":"2003","journal-title":"J Rheumatol"},{"key":"p_27_808","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","volume":"64","author":"Geborek P","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"p_28_809","first-page":"295","volume":"64","author":"Genovese MC","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"p_29_810","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"p_30_811","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","volume":"34","author":"Haraoui B.","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"p_31_812","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1034\/j.1600-0404.2000.101001036.x","volume":"101","author":"Heinzlef O","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"p_32_813","first-page":"2005","author":"Prescribing Information","year":"2005","journal-title":"North Chicago"},{"key":"p_33_814","unstructured":"[HUMIRA PC] HUMIRAR(adalimumab) Summary of Product Characteristics. 2005. Abbott Laboratories, North Chicago, IL, 60064 USA."},{"key":"p_34_815","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","volume":"31","author":"Isomaki HA","year":"1978","journal-title":"J Chronic Dis"},{"key":"p_35_816","first-page":"S132","volume":"45","author":"Kavanaugh A","year":"2002","journal-title":"Arthritis Rheum"},{"key":"p_36_817","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/rheumatology\/keh617","volume":"32","author":"Keystone EC.","year":"2005","journal-title":"J Rheumatol"},{"key":"p_37_818","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard.62.suppl_2.ii34","volume":"62","author":"Keystone E","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"p_38_819","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.62.suppl_2.ii34","volume":"62","author":"Keystone E","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"p_39_820","first-page":"278","volume":"64","author":"Keystone EC","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"p_40_821","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"p_41_822","first-page":"277","volume":"64","author":"Keystone EC","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"p_42_823","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, etal 2004c. Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (Humira) plus methotrexate [abstract]. Arthritis Rheum 50(Suppl):S189 (Poster 371)."},{"key":"p_43_824","unstructured":"Keystone E, Haraoui B, Bykerk VP. 2003. Role of adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Clin Exp Rheumatol, 21(5 Suppl 31):S198-9."},{"key":"p_44_825","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"p_45_826","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/14750708.2.1.13","volume":"2","author":"Lee SJ","year":"2005","journal-title":"Therapy"},{"key":"p_46_827","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"p_47_828","first-page":"S269","volume":"43","author":"Lipsky PE","year":"2000","journal-title":"Arthritis Rheum"},{"key":"p_48_829","unstructured":"Magnano M, Robinson WH, Genovese MC. 2004. Demyelination and the use of TNF inhibition. Clin Exp Rheumatol, 22(5 Suppl 35):S134-40."},{"key":"p_49_830","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"p_50_831","unstructured":"Mease P. 2005. TNF-alpha inhibitors in psoriatic arthritis. In: Gordon KB, Ruderman EM (eds). Psoriasis and psoriatic arthritis: an integrated approach. Springer-Verlag, Heidelberg, Germany, pp 223-34."},{"key":"p_51_832","doi-asserted-by":"crossref","unstructured":"Mease PJ, Antoni CE. 2005. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis, 64(Suppl II):ii78-82.","DOI":"10.1136\/ard.2004.034157"},{"key":"p_52_833","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"p_53_834","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1002\/art.21306","volume":"52","author":"Mease PJ","year":"2005","journal-title":"Arthritis Rheum"},{"key":"p_54_835","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"p_55_836","doi-asserted-by":"crossref","first-page":"S616","DOI":"10.1002\/art.20335","volume":"50","author":"Mease P","year":"2004","journal-title":"Arthritis Rheum"},{"key":"p_56_837","unstructured":"Mease PJ, Ruderman EM, Kivitz AJ, etal 2003. Continued efficacy and safety of etanercept (ENBRELO) in patients with psoriatic arthritis and psoriasis. Arthritis Rheum, 48(9S):(Abstract 343)S169."},{"key":"p_57_838","doi-asserted-by":"crossref","first-page":"S631","DOI":"10.1002\/art.21306","volume":"52","author":"Mease P","year":"2005","journal-title":"Arthritis Rheum"},{"key":"p_58_839","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"Moreland LW","year":"1997","journal-title":"N Engl J Med"},{"key":"p_59_840","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"Moreland LW","year":"1999","journal-title":"Ann Intern Med"},{"key":"p_60_841","doi-asserted-by":"publisher","DOI":"10.1002\/art.10092"},{"key":"p_61_842","first-page":"518","volume":"24","author":"Partsch G","year":"1997","journal-title":"J Rheumatol"},{"key":"p_62_843","first-page":"1544","volume":"25","author":"Ritchlin C","year":"1998","journal-title":"J Rheumatol"},{"key":"p_63_844","unstructured":"Ritchlin CT, Mease PJ, Sasso EH. 2006. Correlation of skin and joint responses in psoriatic arthritis: ADEPT subanalysis. Poster presentation at the Spring Symposium of the European Academy of Dermatology and Venereology (EADV), February 9-12, 2006, Lapland, Finland."},{"key":"p_64_845","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780310816","volume":"31","author":"Saxne T","year":"1988","journal-title":"Arthritis Rheum"},{"key":"p_65_846","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"Schiff MH","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"p_66_847","first-page":"184","volume":"62","author":"Schiff M","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"p_67_848","unstructured":"Strand V, Weisman MH, Nichol MB, etal 2003. Adalimumab improves health-related quality of life in rheumatoid arthritis patients [abstract no. 99]. Arthritis Rheum, 48(9 Suppl):S402."},{"key":"p_68_849","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/ard.62.4.356","volume":"62","author":"Strand V","year":"2003","journal-title":"SAT0246]. Ann Rheum Dis"},{"key":"p_69_850","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4049\/jimmunol.138.3.775","volume":"138","author":"Thomson BM","year":"1987","journal-title":"J Immunol"},{"key":"p_70_851","unstructured":"van der Heijde D, Landewe RBM, Keystone EC, etal 2005. Adalimumab (HUMIRAR) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis. Arthritis Rheum, Suppl:S110 (Poster Presentation 207)."},{"key":"p_71_852","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"van der Heijde D","year":"2005","journal-title":"Arthritis Rheum"},{"key":"p_72_853","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"van der Heijde D","year":"2006","journal-title":"Arthritis Rheum"},{"key":"p_73_854","unstructured":"van de Putte LBA, Salfeld J, Kaymakcalan Z. 2003. Adalimumab. In: Moreland LW, Emery P (eds). TNF-inhibition in the treatment of rheumatoid arthritis. London: Martin Dunitz, pp 71-93."},{"key":"p_74_855","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"van de Putte LB","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"p_75_856","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"p_76_857","first-page":"295","volume":"64","author":"Weinblatt ME","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"p_77_858","unstructured":"Weinblatt ME, Keystone EC, Furst DE, etal 2005. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis in the ARMADA trial [abstract]. Arthritis Rheum, 52(Suppl):S563 (Poster 1497)."},{"key":"p_78_859","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"p_79_860","first-page":"411","volume":"62","author":"Wells AF","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:45:56Z","timestamp":1737110756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/adalimumab-in-the-treatment-of-arthritis-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.2147\/tcrm.2007.3.1.133"],"URL":"https:\/\/doi.org\/10.2147\/tcrm.2007.3.1.133","relation":{},"ISSN":["1176-6336"],"issn-type":[{"value":"1176-6336","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}